$138 Million is the total value of Delphi Management Partners VIII, L.L.C.'s 4 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TNDM | Tandem Diabetes, Inc. | $119,380,000 | +22.6% | 1,000,000 | 0.0% | 86.22% | +12.1% | |
| KPTI | Karyopharm Therapeutics, Inc. | $13,170,000 | -43.6% | 2,263,006 | 0.0% | 9.51% | -48.4% | |
| CALA | Calithera Biosciences, Inc. | $5,290,000 | +4.3% | 2,426,702 | 0.0% | 3.82% | -4.6% | |
| MREO | Mereo BioPharma Group PLCads | $621,000 | -23.7% | 256,734 | 0.0% | 0.45% | -30.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Tandem Diabetes, Inc. | 5 | Q3 2021 | 86.2% |
| Karyopharm Therapeutics, Inc. | 5 | Q3 2021 | 34.2% |
| Calithera Biosciences, Inc. | 5 | Q3 2021 | 10.9% |
| Mereo BioPharma Group PLC | 5 | Q3 2021 | 0.7% |
| Senseonics Holdings, Inc. | 3 | Q1 2021 | 18.0% |
View Delphi Management Partners VIII, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-12 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-08 |
| 13F-HR | 2020-02-07 |
| 4 | 2016-03-23 |
| 3 | 2016-03-17 |
| 4 | 2016-02-05 |
| 4 | 2014-10-09 |
| 3 | 2014-10-01 |
View Delphi Management Partners VIII, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.